NUREXONE BIOLOGIC INC. (J90) — Financial Flexibility Index
NUREXONE BIOLOGIC INC. (J90) has a Financial Flexibility Index of -0.88x as of December 2025. Free cash flow of €-1.17 Million (operating CF €-1.17 Million minus capex €9.00K) represents -1% of total liabilities (€1.32 Million). Check J90 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
NUREXONE BIOLOGIC INC. Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for NUREXONE BIOLOGIC INC. across 5 annual periods. For the full cash flow conversion analysis, see NUREXONE BIOLOGIC INC. (J90) cash conversion ratio.
Annual Financial Flexibility Index for NUREXONE BIOLOGIC INC. (2021–2025)
Year-by-year free cash flow to debt coverage for NUREXONE BIOLOGIC INC.. Explore J90 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -3.36x | €-4.46 Million | €-4.51 Million | €1.32 Million | ▲ +46.1% |
| 2024 | -6.23x | €-4.24 Million | €-4.89 Million | €680.00K | ▼ -337.8% |
| 2023 | -1.42x | €-2.82 Million | €-2.94 Million | €1.98 Million | ▲ +73.8% |
| 2022 | -5.44x | €-3.80 Million | €-3.85 Million | €698.00K | ▼ -632.3% |
| 2021 | -0.74x | €-1.23 Million | €-1.23 Million | €1.66 Million | — |